

PRESS INFORMATION



biolitec AG
Otto-Schott-Str. 15
07745 Jena
www.biolitec.de

biolitec AG increases group revenue to Euro 10.1 million in the first quarter of the fiscal year 2012/13

Sales increase of 1.1 million compared to last year period – Transfer of registered office to Austria completed – Continued growth expected

Jena, March 18, 2013 – The merging companies biolitec AG (ISIN DE0005213409), Jena, listed in the Prime Standard of the Frankfurt stock exchange resp. biolitec UBI AG (ISIN AT0000A0VCT2), Vienna, listed in the Entry Standard, achieved a group revenue of Euro 10.07 million in the first quarter of the fiscal year 2012/2013. Thereby, the revenue was Euro 1.1 million above the same period in the previous year. The revenue growth of more than 12.3% is attributable to the growing demand for biolitec's mainstays of sales, the LIFE™ laser treatment of benign prostate hyperplasia (BPH) and the endoluminal laser treatment of veins (ELVeS®). But also new therapies such as the outstanding new development in gynaecology, the revolutionary laser system HOLA™ (Hysteroscopic Outpatient Laser Applications) for the treatment of myomas, or the laser therapy for haemorrhoids of higher grades, the so called Laser HaemorrhoidoPlasty (LHP™), provide pleasing prospects in the medium term.

The gross profit amounted to Euro 7.3 million (previous year: Euro 5.8 million) and EBIT declined to Euro 0.46 million (previous year: Euro 0.97 million).

R&D expenditures for the first quarter of the fiscal year 2012/2013 of Euro 0.94 million (about 9% of sales) compared to the previous year (Euro 0.8 million) remain unchanged (in terms of percentage) on the required level to ensure the company's long term growth and profitability. Sales costs were increased to Euro 3.0 million (compared to Euro 2.3 million in the last year's period). Earnings per share were at Euro 0.04 in comparison to Euro 0.08 in the same period of the previous year.

Major revenues of biolitec AG, Jena resp. Vienna, were generated in Europe and North America. With Euro 3.6 million, sales in North America increased by +5% compared to previous year's level. European sales amounted to Euro 3.0 million (previous year: Euro 3.3 million). Our foreign subsidiaries, especially in the Arabian region and Asia, contribute increasingly to overall results and showed pleasingly high growth rates of

PRESS INFORMATION



biolitec AG

Otto-Schott-Str. 15

07745 Jena

www.biolitec.de

+57% to Euro 3.5 million in comparison to the first quarter of the previous year. biolitec's medium-term goal to increase these markets' proportion of sales up to one third and thus lay the basis of further growth adapted to the world market situation could thus be achieved in the first quarter of the fiscal year 2012/2013.

Sales in the business segment Meditec increased by +17% to Euro 9.9 million in the first quarter; in the Pharma segment, the sales amounted to modest Euro 0.13 million.

The preparation of the annual financial statement 2011/2012 has been delayed longer than expected due to increased auditing work and the merger process. biolitec has decided to publish the first quarter of 2012/2013 even without available audit for the annual financial statement 2011/2012 in order to provide its shareholders with the fullest possible information about the company's situation. The fiscal year 2011/2012 closed with an un-audited loss of Euro -5.2 million.

At the Extraordinary General Meeting on August 30, 2012, shareholder of biolitec AG, Jena, decided by a large majority to relocate the company's registered office to Austria. As a result of relocating to Austria and the downstream merger associated with it in the entry standard, biolitec AG will be able to utilise the options of tax optimisation, which includes the option of Austrian group taxation. In addition, it will also be geographically closer to the growing markets of the future in Eastern Europe. The legal merger of biolitec AG, Jena, into biolitec Unternehmensbeteiligungs I AG, Vienna, was executed on March 15, 2013.

For the current business year biolitec expect continued growth.

About biolitec®:

biolitec® AG is one of the leading companies worldwide in the field of medical laser treatments und the only provider that possesses all relevant core competencies – photosensitizers, laser devices and optical fibres – in the field of photodynamic therapy (PDT). Besides the laser treatment of cancer with Foscan®, biolitec® primarily researches on minimally-invasive and gentle laser treatments and markets them. ELVeS Radial™ (Endo Laser Vein System) the laser system is most often used worldwide for the treatment of varicose veins. Ceralas® HPD laser therapy enables a gentle treatment of e.g. benign prostatic hyperplasia (BPH) in urology. Gentle laser treatments in the fields of proctology, ENT, orthopaedics, gynaecology as well as optalmology also belong to the business field of biolitec®. biolitec® AG, Jena, is listed in the Prime Standard (ISIN DE0005213409), and biolitec UBI, Vienna (ISIN AT0000A0VCT2) in the Entry Standard. Further information at www.biolitec.de.

Investor Relations

Jörn Gleisner

Tel.: +49 (0) 3641/5195336

Fax: +49 (0) 3641/5195333

E-mail: joern.gleisner@biolitec.com